GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cohance Lifesciences Ltd (BOM:543064) » Definitions » EV-to-Revenue

Cohance Lifesciences (BOM:543064) EV-to-Revenue : 32.80 (As of Jun. 03, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Cohance Lifesciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cohance Lifesciences's enterprise value is ₹392,866 Mil. Cohance Lifesciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₹11,976 Mil. Therefore, Cohance Lifesciences's EV-to-Revenue for today is 32.80.

The historical rank and industry rank for Cohance Lifesciences's EV-to-Revenue or its related term are showing as below:

BOM:543064' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.96   Med: 11.64   Max: 34.7
Current: 32.81

During the past 7 years, the highest EV-to-Revenue of Cohance Lifesciences was 34.70. The lowest was 2.96. And the median was 11.64.

BOM:543064's EV-to-Revenue is ranked worse than
94.96% of 973 companies
in the Drug Manufacturers industry
Industry Median: 2.43 vs BOM:543064: 32.81

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-03), Cohance Lifesciences's stock price is ₹1023.45. Cohance Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ₹47.47. Therefore, Cohance Lifesciences's PS Ratio for today is 21.56.


Cohance Lifesciences EV-to-Revenue Historical Data

The historical data trend for Cohance Lifesciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cohance Lifesciences EV-to-Revenue Chart

Cohance Lifesciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EV-to-Revenue
Get a 7-Day Free Trial 12.62 11.71 8.73 15.66 24.76

Cohance Lifesciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.66 21.90 30.47 27.58 24.76

Competitive Comparison of Cohance Lifesciences's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cohance Lifesciences's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cohance Lifesciences's EV-to-Revenue falls into.


;
;

Cohance Lifesciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cohance Lifesciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=392865.539/11975.8
=32.80

Cohance Lifesciences's current Enterprise Value is ₹392,866 Mil.
Cohance Lifesciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11,976 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cohance Lifesciences  (BOM:543064) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cohance Lifesciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1023.45/47.469
=21.56

Cohance Lifesciences's share price for today is ₹1023.45.
Cohance Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹47.47.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cohance Lifesciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cohance Lifesciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cohance Lifesciences Business Description

Traded in Other Exchanges
Address
Hitech City Road, Panmaktha Plot, 1, 202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad Knowledge City TSIIC Raidurg, Opposite IKEA, Hyderabad, TG, IND, 500081
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.

Cohance Lifesciences Headlines

No Headlines